Sunday, January 1, 2012

What Causes a Black Colored Tongue?

Patient Presentation
A 14-year-old caucasian male came to clinic because he had noticed his tongue becoming darker over the previous week. He was very concerned about the coloring as he said it would not go away. He was studying for school examinations and had been self-medicating an upset stomach with Pepto-Bismol®. About 1 month ago he was diagnosed with bronchitis at an urgent care center and had taken antibiotics. The past medical history was negative except for being overweight. The review of systems was negative. The pertinent physical exam showed a well-appearing male whose BMI was 28.9 with normal vital signs. HEENT showed poor oral hygiene with obvious caries. He had dark brown coloring of the top of the tongue anteriorly, not involving the sides, that was uniform. Scraping appeared to decrease the discoloration but it didn’t completely go away. There was no elevation of the tongue nor oral masses visible or palpable. There were some shoddy anterior cervical nodes. His neck had a normal thyroid examination and no masses. Skin examination showed acne on his face, and a few brown macules and freckles scattered on his trunk, arms and face that he reported to be unchanged. He had no discoloration of the palms or soles. The diagnosis of poor oral hygiene along with taking bismuth was made. He was counseled about the bismuth use and school stress. He was also counseled about oral hygiene including scraping of his tongue. Followup at 1 month showed that the discoloration had resolved and his stress after examinations.

Discussion
Although dental caries, strep throat and oral candidiasis are some of the most common oral pathology. The tongue itself can be a source of potential pathology. Geographic tongue, oral candidiasis, and lingual ulcerations are common problems. Most discolorations of the tongue are because of food, drink or medications that are ingested and are self-limited. However discoloration can be a sign of more significant problems.
Hairy tongue, often colored black, is a relatively uncommon problem in the US but has a higher incidence reported in Turkey and Iran. It is more common in adults than children but has been reported in a child 2 months of age. It is also called lingua villosa nigra and is a benign condition caused by keratin accumulation usually in the setting of poor oral hygiene and/or xerostomia. The accumulation is on the filliform papillae and will be seen on the dorsal surface anterior to the circumvallate papillae and not on the lateral sides of the tongue or tip. The discoloration can be different colors depending on the oral flora. Hairy tongue usually responds to oral hygiene including scraping of the tongue, but sometimes retinoids, keratolytic agents and other treatments are used.


Learning Point
The differential diagnosis of a black tongue includes:

Normal variation Poor oral hygiene Acanthosis nigracans Adrenal insufficiency Congenital lingual melanotic macules Congenital melanocytic naeviDrugs Antibiotics use Linzezold Minocycline Graft vs. Host Disease Heavy metals Infection Candida Kocuria (Micrococcus) kristinaeLingua villosa nigra “Black hairy tongue” Lupus (possibly associated) Neurofibromatosis Oncological Peutz Jegher Staining Bismuth Food coloring including coffee, tea Smoking

Questions for Further Discussion
1. What is the differential diagnosis of white lesions in the mouth?
2. What are the indications for referral for discoloration of the tongue and to whom would you refer?


Related Cases


To Learn More
To view pediatric review articles on this topic from the past year check PubMed.

Evidence-based medicine information on this topic can be found at SearchingPediatrics.com, the National Guideline Clearinghouse and the Cochrane Database of Systematic Reviews.


Information prescriptions for patients can be found at MedlinePlus for this topic: Tongue Disorders

To view current news articles on this topic check Google News.

To view images related to this topic check Google Images.

McGrath EE, Bardsley P, Basran G. Black hairy tongue: what is your call? CMAJ. 2008 Apr 22;178(9):1137-8.

Akl KF. Black tongue. J Paediatr Child Health. 2009 Jan-Feb;45(1-2):73-4.

Akay BN, Sanli H, Topcuoglu P, Zincircioglu G, Gurgan C, Heper AO. Black hairy tongue after allogeneic stem cell transplantation: an unrecognized cutaneous presentation of graft-versus-host disease. Transplant Proc. 2010 Dec;42(10):4603-7.

Thompson DF, Kessler TL. Drug-induced black hairy tongue. Pharmacotherapy. 2010 Jun;30(6):585-93.

Nisa L, Giger R. Black hairy tongue. Am J Med. 2011 Sep;124(9):816-7.

Oncel EK, Boyraz MS, Kara A. Black tongue associated with Kocuria (Micrococcus) kristinae bacteremia in a 4-month-old infant. Eur J Pediatr. 2011 Sep 21.

Guinovart RM, Carrascosa JM, Bielsa I, Rodriguez C, Ferrandiz C. A black tongue in a young woman. Clin Exp Dermatol. 2011 Jun;36(4):429-30.

ACGME Competencies Highlighted by Case

Patient Care
1. When interacting with patients and their families, the health care professional communicates effectively and demonstrates caring and respectful behaviors.
2. Essential and accurate information about the patients’ is gathered.
3. Informed decisions about diagnostic and therapeutic interventions based on patient information and preferences, up-to-date scientific evidence, and clinical judgment is made.
4. Patient management plans are developed and carried out.
5. Patients and their families are counseled and educated.
8. Health care services aimed at preventing health problems or maintaining health are provided. Medical Knowledge
10. An investigatory and analytic thinking approach to the clinical situation is demonstrated.
11. Basic and clinically supportive sciences appropriate to their discipline are known and applied. Interpersonal and Communication Skills
17. A therapeutic and ethically sound relationship with patients is created and sustained.
18. Using effective nonverbal, explanatory, questioning, and writing skills, the healthcare professional uses effective listening skills and elicits and provides information.
19. The health professional works effectively with others as a member or leader of a health care team or other professional group.

Author

Donna M. D’Alessandro, MD
Professor of Pediatrics, University of Iowa Children’s Hospital

This entry was posted on Monday, December 19th, 2011 at 12:29 am and is filed under Uncategorized. You can follow any responses to this entry through the RSS 2.0 feed. Both comments and pings are currently closed.


View the original article here

XOMA Initiates Gevokizumab Phase 2 Study for Moderate to Severe Acne Vulgaris

BERKELEY, Calif., Dec. 21, 2011 (GLOBE NEWSWIRE) -- XOMA Ltd. (Nasdaq:XOMA) today announced it has begun dosing patients in its Phase 2 proof-of-concept study to evaluate the efficacy and safety of gevokizumab (XOMA 052), a potent inhibitor of interleukin-1 beta (IL-1 beta), for the treatment of the inflammatory lesions seen in moderate to severe acne vulgaris. Approximately 170 patients will be randomized to receive one of two dose levels of gevokizumab or placebo administered subcutaneously over a three-month period. The primary study efficacy endpoint is the mean absolute change from baseline in inflammatory facial lesion count after three months of therapy. Additional study information has been submitted for publication on www.clinicaltrials.gov

"XOMA's Phase 2 proof-of-concept program is designed to expand the value of gevokizumab, the company's lead clinical asset, by demonstrating its potential in diseases characterized by interleukin-1 beta over-expression. This is the first in a series of clinical studies that we plan to conduct in separate indications over the next 12 to 18 months," commented John Varian, Interim Chief Executive Officer of XOMA Ltd. "Upon completion of this series of proof-of-concept studies, we believe we will have sufficient evidence to initiate a further development program in at least one of these indications."

Moderate to severe acne vulgaris is estimated to affect approximately three to four million people in the U.S. Acne is characterized by the presence of a bacteria known as Proprionumbacterium acne, which promotes the production of proinflammatory substances including IL-1 beta in experimental models of the disease.

Moderate to severe acne that does not respond to topical agents is often treated with orally administered antibiotics. For the most severe, non-responsive acne, isotretinoin (an oral retinoid drug) treatment may be prescribed, although it is only available through a restricted distribution program due to its side effect profile.

About Gevokizumab and Interleukin-1 Inhibition

Gevokizumab (XOMA 052) is a potent monoclonal antibody with the potential to treat patients with a wide variety of inflammatory and other diseases. Gevokizumab binds strongly to interleukin-1 beta (IL-1 beta), a pro-inflammatory cytokine that has been shown to be involved in non-infectious uveitis including Behçet's uveitis, cardiovascular disease, and other auto-inflammatory diseases. By binding to IL-1 beta, gevokizumab inhibits the activation of the IL-1 receptor, thereby modulating the cellular signaling events that produce inflammation.

Gevokizumab has been studied in nearly 500 patients, with approximately 300 patients on treatment for six months, and has been shown to be well-tolerated. As previously reported, in a proof-of-concept Phase 2 trial of gevokizumab in Behçet's uveitis, all seven patients displayed rapid reduction of intraocular inflammation and improvement in visual acuity or other ophthalmic measures after a single treatment and following discontinuation of immunosuppressive drugs such as cyclosporine and/or azathioprine. Five of the patients were retreated with gevokizumab due to a recurring uveitis exacerbation and all responded again to treatment. Due to its ability to reduce C-reactive protein, gevokizumab also has potential for the treatment of cardiovascular and other inflammatory diseases.

About XOMA

XOMA is a leader in the discovery and development of novel antibody therapeutics. The company's proprietary product pipeline includes:

Gevokizumab (XOMA 052), a humanized antibody that binds to the inflammatory cytokine interleukin-1 beta, or IL-1 beta. XOMA plans to enter gevokizumab into Phase 3 clinical development in non-infectious uveitis affecting the intermediate and/or posterior segments of the eye, and has initiated a Phase 2 proof-of-concept trial for the treatment of moderate and severe acne vulgaris. Les Laboratoires Servier is XOMA's development and commercialization partner for gevokizumab. XOMA holds rights to gevokizumab in the U.S. and Japan for all non-cardiovascular and non-diabetes indications, including acne vulgaris, uveitis and Behçet's uveitis.Antibodies against botulinum toxins, led by XOMA 3AB, a novel combination of three antibodies to prevent and treat botulism poisoning caused by exposure to botulinum neurotoxin Type A, among the most deadly bioterror threats. XOMA 3AB is in a Phase 1 clinical trial sponsored by the National Institute of Allergy and Infectious Diseases (NIAID) of the National Institutes of Health (NIH). Development of these antibodies has been funded in whole or in part with funds from NIAID, NIH, Department of Health and Human Services under Contract No. HHSN266200500004C, Contract No. HHSN266200600008C, Contract No. HHSN272200800028C, Contract No. HHSN266200600011C, Contract No., HHSN272200800026C, and Contract No. HHSN2722011031C.A preclinical pipeline with candidates in development for autoimmune, cardio-metabolic, inflammatory and oncological diseases. Among these are two new classes of fully human monoclonal antibodies that activate (XMetA) or sensitize (XMetS) the insulin receptor in vivo, which represent distinct new therapeutic approaches to the treatment of patients with diabetes.

XOMA has a premier antibody discovery and development platform that incorporates an unmatched collection of antibody phage display libraries and proprietary optimization and expression and manufacturing technologies that it uses for its own pipeline and in collaborations with pharmaceutical and biotechnology companies. XOMA's fully integrated product development infrastructure extends from preclinical science to approval and is located in Berkeley, California. For more information, please visit www.xoma.com.

The XOMA Ltd. logo is available at http://www.globenewswire.com/newsroom/prs/?pkgid=5960

Forward-Looking Statements

Certain statements contained herein concerning Phase 2 clinical trials or product development, or that otherwise relate to future periods are forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. These statements are based on assumptions that may not prove accurate. Actual results could differ materially from those anticipated due to certain risks inherent in the biotechnology industry and for companies engaged in the development of new products in a regulated market.

Among other things, clinical trials may not be successful in achieving their goals, whether due to lack of efficacy or for safety, statistical or other reasons, and results of earlier-stage clinical trials may not be supported by results of later-stage trials.

These and other risks, including those related to the generally unstable nature of current economic and financial market conditions; the results of discovery and pre-clinical testing; the timing or results of pending and future clinical trials (including the design and progress of clinical trials; safety and efficacy of the products being tested; action, inaction or delay by the FDA, European or other regulators or their advisory bodies; and analysis or interpretation by, or submission to, these entities or others of scientific data); changes in the status of existing collaborative or licensing relationships; the ability of collaborators, licensees and other third parties to meet their obligations and their discretion in decision-making; XOMA's ability to meet the demands of the United States government agency with which it has entered into its government contracts; competition; market demand for products; scale-up, manufacturing and marketing capabilities; availability of additional licensing or collaboration opportunities; international operations; share price volatility; XOMA's financing needs and opportunities; uncertainties regarding the status of biotechnology patents; uncertainties as to the costs of protecting intellectual property; and risks associated with XOMA's status as a Bermuda company, are described in more detail in XOMA's most recent filing on Form 10-K and in other SEC filings. Consider such risks carefully when considering XOMA's prospects.

CONTACT: XOMA Ltd. Company and Investor Contact: Carol DeGuzman 510-204-7270 deguzman@xoma.com Canale Communications Media Contact: Pam Lord 619-849-6003 pam@canalecomm.com